BMY Shareholders' equity
Shareholders' equity at Bristol Myers Squibb rose to $18.5B in fiscal 2025, from $16.3B in 2024.
Stockholders' equity attributable to the parent, as filed.
SOURCE: us-gaap:StockholdersEquity · EDGAR CompanyFacts · CIK 14272 · EDGAR ↗ · FY2021–FY2025 · ANNUAL
FY2025$18.5B
FY2024 $16.3B
HIGH$35.9B FY2021
LOW$16.3B FY2024
History AS FILED · DERIVATION SHOWN WHERE DERIVED
| Fiscal year | Shareholders' equity | Change |
|---|---|---|
| FY2025 | $18.5B | +$2.1B |
| FY2024 | $16.3B | $-13.1B |
| FY2023 | $29.4B | $-1.6B |
| FY2022 | $31.1B | $-4.9B |
| FY2021 | $35.9B | — |
More SAME DATA, OTHER VIEWS
Shareholders' equity across coverage → · BMY company view →
Revenue · Net income · Operating cash flow · Free cash flow · Capital expenditure · Cash & equivalents · Total assets · Total debt · Return on equity · Days sales outstanding
Not investment advice. Every figure on this page is an XBRL fact from the issuer's own SEC filings or an arithmetic over such facts with the method shown. No forecast is made; no posture is expressed.